UY36356A - Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis - Google Patents
Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosisInfo
- Publication number
- UY36356A UY36356A UY0001036356A UY36356A UY36356A UY 36356 A UY36356 A UY 36356A UY 0001036356 A UY0001036356 A UY 0001036356A UY 36356 A UY36356 A UY 36356A UY 36356 A UY36356 A UY 36356A
- Authority
- UY
- Uruguay
- Prior art keywords
- osteoporosis
- prevention
- treatment
- pharmaceutical compositions
- aromatic compounds
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 150000001491 aromatic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000011690 Adiponectin Human genes 0.000 abstract 1
- 108010076365 Adiponectin Proteins 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 230000033558 biomineral tissue development Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000010072 bone remodeling Effects 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 230000004072 osteoblast differentiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al uso de compuestos para prevenir y/o tratar la osteoporosis, para estimular la formación ósea, para estimular la remodelación ósea, para estimular la diferenciación y la mineralización de los osteoblastos, para inhibir la resorción ósea y para modular el nivel en suero de adiponectina en un sujeto. Estos usos novedosos se han descubierto para los compuestos representados por la fórmula I descritos en la presente solicitud y las sales farmacéuticamente aceptables de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062597P | 2014-10-10 | 2014-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36356A true UY36356A (es) | 2016-06-01 |
Family
ID=55652429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036356A UY36356A (es) | 2014-10-10 | 2015-10-13 | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20180228750A1 (es) |
| EP (1) | EP3203999B1 (es) |
| JP (1) | JP6700639B2 (es) |
| KR (1) | KR20170066476A (es) |
| CN (1) | CN106999456B (es) |
| AR (1) | AR102246A1 (es) |
| AU (1) | AU2015330645B2 (es) |
| BR (1) | BR112017007426A2 (es) |
| CA (1) | CA2963354A1 (es) |
| DK (1) | DK3203999T3 (es) |
| ES (1) | ES2785317T3 (es) |
| IL (1) | IL251404B (es) |
| MX (1) | MX2017004733A (es) |
| MY (1) | MY194308A (es) |
| PH (1) | PH12017500638A1 (es) |
| PL (1) | PL3203999T3 (es) |
| PT (1) | PT3203999T (es) |
| RU (1) | RU2709205C2 (es) |
| SG (1) | SG11201702868VA (es) |
| TW (1) | TWI699200B (es) |
| UY (1) | UY36356A (es) |
| WO (1) | WO2016054728A1 (es) |
| ZA (1) | ZA201702639B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3217968A4 (en) | 2014-11-12 | 2018-06-20 | Prometic Pharma Smt Limited | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| AU2017313842A1 (en) * | 2016-08-18 | 2019-03-07 | Intekrin Therapeutics, Inc. | PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
| WO2022073115A1 (en) * | 2020-10-06 | 2022-04-14 | Biopharmaceutiques Ingenew Inc. | Substituted aromatic compounds and pharmaceutical compositions thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863270B2 (en) * | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| MY156780A (en) * | 2009-05-04 | 2016-03-31 | Prometic Biosciences Inc | Substituted aromatic compounds and pharmaceutical uses thereof |
| JP5844251B2 (ja) * | 2009-05-04 | 2016-01-13 | プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． | ３−ペンチルフェニル酢酸の塩およびその薬学的使用 |
| US9475750B2 (en) * | 2010-10-27 | 2016-10-25 | Prometic Biosciences Inc. | Phenylketone carboxylate compounds and pharmaceutical uses thereof |
| CN103347509B (zh) * | 2010-10-27 | 2016-06-08 | 普罗米蒂克生物科学公司 | 用于治疗癌症的化合物和组合物 |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
-
2015
- 2015-10-08 CA CA2963354A patent/CA2963354A1/en not_active Abandoned
- 2015-10-08 JP JP2017518905A patent/JP6700639B2/ja not_active Expired - Fee Related
- 2015-10-08 EP EP15849675.2A patent/EP3203999B1/en active Active
- 2015-10-08 DK DK15849675.2T patent/DK3203999T3/da active
- 2015-10-08 PT PT158496752T patent/PT3203999T/pt unknown
- 2015-10-08 US US15/516,643 patent/US20180228750A1/en not_active Abandoned
- 2015-10-08 KR KR1020177011332A patent/KR20170066476A/ko not_active Application Discontinuation
- 2015-10-08 MX MX2017004733A patent/MX2017004733A/es active IP Right Grant
- 2015-10-08 PL PL15849675T patent/PL3203999T3/pl unknown
- 2015-10-08 TW TW104133254A patent/TWI699200B/zh not_active IP Right Cessation
- 2015-10-08 AU AU2015330645A patent/AU2015330645B2/en not_active Ceased
- 2015-10-08 ES ES15849675T patent/ES2785317T3/es active Active
- 2015-10-08 SG SG11201702868VA patent/SG11201702868VA/en unknown
- 2015-10-08 CN CN201580058623.7A patent/CN106999456B/zh not_active Expired - Fee Related
- 2015-10-08 WO PCT/CA2015/000540 patent/WO2016054728A1/en active Application Filing
- 2015-10-08 MY MYPI2017000520A patent/MY194308A/en unknown
- 2015-10-08 BR BR112017007426-5A patent/BR112017007426A2/pt not_active Application Discontinuation
- 2015-10-08 RU RU2017116178A patent/RU2709205C2/ru active
- 2015-10-13 AR ARP150103294A patent/AR102246A1/es unknown
- 2015-10-13 UY UY0001036356A patent/UY36356A/es not_active Application Discontinuation
-
2017
- 2017-03-27 IL IL251404A patent/IL251404B/en active IP Right Grant
- 2017-04-06 PH PH12017500638A patent/PH12017500638A1/en unknown
- 2017-04-12 ZA ZA2017/02639A patent/ZA201702639B/en unknown
-
2020
- 2020-04-09 US US16/844,813 patent/US11185521B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017004733A (es) | 2017-07-17 |
| EP3203999A1 (en) | 2017-08-16 |
| IL251404A0 (en) | 2017-05-29 |
| EP3203999A4 (en) | 2018-06-27 |
| US20180228750A1 (en) | 2018-08-16 |
| KR20170066476A (ko) | 2017-06-14 |
| US11185521B2 (en) | 2021-11-30 |
| BR112017007426A2 (pt) | 2018-01-16 |
| CN106999456A (zh) | 2017-08-01 |
| ES2785317T3 (es) | 2020-10-06 |
| RU2017116178A (ru) | 2018-11-19 |
| AR102246A1 (es) | 2017-02-15 |
| DK3203999T3 (da) | 2020-03-30 |
| TW201618762A (zh) | 2016-06-01 |
| PH12017500638A1 (en) | 2017-09-25 |
| ZA201702639B (en) | 2018-06-27 |
| CA2963354A1 (en) | 2016-04-14 |
| AU2015330645A1 (en) | 2017-05-04 |
| IL251404B (en) | 2020-11-30 |
| US20200237693A1 (en) | 2020-07-30 |
| TWI699200B (zh) | 2020-07-21 |
| SG11201702868VA (en) | 2017-05-30 |
| CN106999456B (zh) | 2020-07-10 |
| JP6700639B2 (ja) | 2020-05-27 |
| PL3203999T3 (pl) | 2020-07-27 |
| EP3203999B1 (en) | 2020-01-08 |
| AU2015330645B2 (en) | 2020-03-12 |
| PT3203999T (pt) | 2020-04-23 |
| RU2709205C2 (ru) | 2019-12-17 |
| JP2017530180A (ja) | 2017-10-12 |
| RU2017116178A3 (es) | 2019-05-16 |
| MY194308A (en) | 2022-11-27 |
| WO2016054728A1 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| UY36356A (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
| CR20190446A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA032928B1 (ru) | Бициклические кетосульфонамидные соединения | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| CO6710916A2 (es) | Inhibidores de notum pectinacetilesterasa y métodos de su uso | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| UY36354A (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes | |
| UY36355A (es) | Compuestos de carboxilato de fenilcetona y composicionesfarmacéuticas para la prevención y tratamiento de osteoporosis | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| BR112016021727A2 (pt) | Antagonistas de mglu2/3 para o tratamento de incapacidades intelectuais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20230508 |